Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). [ Read More ]
The intrinsic value of one MRNA stock under the Base Case scenario is 39.47 USD. Compared to the current market price of 103.29 USD, Moderna Inc is Overvalued by 62%.
Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up to access Moderna Inc's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
Look for stocks that have been historically overvalued but are now trading below their intrinsic value.
Avoid stocks that are always undervalued and never reach their intrinsic value.
Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
Last Video News
Last Important Events
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Cambridge, Massachusetts and currently employs 2,700 full-time employees. The company went IPO on 2018-12-07. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The company is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The firm develops technologies that enable the development of mRNA medicines for diverse applications. The company has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The firm develops technologies that enable the development of mRNA medicines.